New report highlights that declining investment could slow research and rollout of new HIV prevention options

July 17, 2014

The HIV Vaccines & Microbicides Resource Tracking Working Group (RTWG) released its annual report on the state of HIV prevention research funding.

Click here for a press release detailing key findings.

The report, HIV Prevention Research & Development Investment in 2013: In a changing global development, economic and human rights landscape, is the 10th annual update from the RTWG, which is led by AVAC in partnership with the International AIDS Vaccine Initiative and UNAIDS.

The Report tracks spending on HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention, voluntary medical male circumcision, female condoms and prevention of vertical transmission. This year’s report also provides an update on investment in HIV cure, therapeutic vaccine, multipurpose prevention technology and HSV-2 research.

The RTWG has prepared a range of resources to help advocates understand and use the information it contains. One key finding is that there has been a decline in investment from 2012—advocacy is needed to ensure that support for research is sustained.

Specifically, the Report shows that investment in HIV prevention research fell 4 percent in 2013, due to a combination of factors including declining investments by the United States and European donors, changes in the international development landscape and changes in the pipeline of HIV prevention products being tested. In 2013, total investment in prevention research was US $1.26 billion, down US$50 million from 2012.

The full report, a one-page overview of the findings and downloadable graphics are all available at You can also view previous years’ reports. As always, please feel free to contact us with any questions or comments.